Planned Time Burden for Patients Participating in Phase 2 Cancer Trials
Patients in phase 2 cancer trials commit a substantial amount of time to research participation. Further work is needed to compare these estimates to time spent in standard of care, and to find ways to reduce the time toxicity of trial participation.
Authors
- Renata Iskander (ORCID: https://orcid.org/0000-0002-2959-1970)
- R. Nipp
- Charlotte Ouimet (ORCID: https://orcid.org/0000-0001-5465-2256)
- Jonathan Kimmelman
Institutions
- McGill University Health Centre (CA)
- Oklahoma State University Oklahoma City (US)
- University of Oklahoma Health Sciences Center (US)
- McGill University (CA)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1093/oncolo/oyag096
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00